Patients with Crohn’s disease who experience an initial response to ustekinumab are likely to maintain response after two years of continued treatment, new data show.
The findings come from the ongoing IM-UNITI long-term extension study of ustekinumab (Stelara, Janssen) in people with moderate to severe Crohn’s. So far, prolonged treatment with the drug appears safe, according to the investigators.
“Ustekinumab seems like a very attractive agent that is likely to displace TNF